VADS DEBIO 1143-202 Pre-operative window-of-opportunity study of Debio 1143 with or without cisplatin in patients with resectable squamous cell carcinoma of the head and neck. Paris CHRISTOPHE LE TOURNEAU
Gynécologie GM102 OPEN, NON CONTROLLED, MULTICENTER, FIRST-IN-HUMAN STUDY FOR THE EVALUATION OF THE SAFETY, PHARMACOKINETICS AND PRELIMINARY ANTITUMOR ACTIVITY OF GM102 IN PATIENTS WITH ADVANCED PRETREATED GYNECOLOGICAL CANCER Paris CHRISTOPHE LE TOURNEAU
VADS NBTXR3-102 A Phase I Dose-Escalation Study of NBTXR3 Activated by Intensity Modulated Radiation Therapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or Oropharynx Paris CHRISTOPHE LE TOURNEAU
VADS U31287-A-U203 / Patritumab RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND PHASE 2 STUDY OF PATRITUMAB (U3-1287) IN COMBINATION WITH CETUXIMAB PLUS PLATINUM-BASED THERAPY IN FIRST LINE SETTING IN SUBJECTS WITH RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK. Paris CHRISTOPHE LE TOURNEAU
Sein métastatique RH+ SAFIR PI3K A Phase II Randomized Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy as Maintenance Therapy in Patients With PIK3CA Mutated Advanced Breast Cancer Paris, Saint-Cloud
VADS TOPNIVO - ORL09 A Safety study of Nivolumab in Patients with Recurrent and/or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN). Paris CHRISTOPHE LE TOURNEAU
VADS UP-STREAM ( EORTC 1559-HNCG) A Pilot Study of Personalized Biomarker-based Treatment Strategy or Immunotherapy in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck. Paris CHRISTOPHE LE TOURNEAU
Sein métastatique triple négatif CO40151 A phase ib, open-label, multicenter study evaluating the safety and efficacy of ipatasertib in combination with atezolizumab and paclitaxel or nab-paclitaxel in patients with locally advanced or metastatic triple- negative breast cancer Paris
Appareil Digestif SCARCE (C17-02 PRODIGE 60) A Non-comparative Randomized 2:1 Phase II Study of Docetaxel, Cisplatin, and 5-fluorouracil in Combination or Not With Atezolizumab in Patients With Metastatic or Unresectable Locally Advanced Squamous Cell Anal Carcinoma Paris
Sein métastatique RH+ XENERA-1 (BI 1280-0022) A multi-centre, double-blind, placebo-controlled,randomised phase II trial to compare efficacy of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in post-menopausal women with HR+ / HER2- metastatic breast cancer and non-visceral disease Paris